NCT02778685View on ClinicalTrials.gov

Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

March 30, 2026

Study Completion Date

March 30, 2026

Conditions
Metastatic Breast CarcinomaStage IV Breast Cancer AJCC v6 and v7
Interventions
DRUG

Fulvestrant

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Letrozole

Given PO

DRUG

Palbociclib

Given PO

BIOLOGICAL

Pembrolizumab

Given IV

Trial Locations (7)

91010

City of Hope Medical Center, Duarte

91030

City of Hope South Pasadena, South Pasadena

91345

City of Hope Mission Hills, Mission Hills

91786

City of Hope Upland, Upland

91790

City of Hope West Covina, West Covina

92879

City of Hope Corona, Corona

93534

City of Hope Antelope Valley, Lancaster

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER